Abstract 872
Background
The present study aimed to compare the protein profiles between paired samples of cervical cancer and paracancerous tissue and to identify a series of differentially expressed proteins (DEPs) through quantitative proteomics.
Methods
The DEPs were identified through proteomic profiles of three paired samples of cervical cancer (CC) and paracancerous tissue and through IHC examination in the CC tissue arrays. The lentiviral particles containing DUSP7 gene were transfected into SIHA cells (DUSP7-SIHA). CCK8 assay, colony formation assay, wound healing assay and transwell migration assay were used to evaluate the ability of cell proliferation, cell clone formation, cell migration and invasion. Immunofluorescence assay was used to detect the expression of E-cadherin and Vimentin in the target cells.
Results
The decreased expression of DUSP7 (P = 0.045 and 0.044, respectively) and increased expression of PLD1 (P = 0.046 and 0.028, respectively) were significantly associated with a tumor size >2cm and parametrial infiltration. The decreased expression of DUSP7, and increased expression of PLD1 were adversely related to patients’ relapse (P = 0.003, 0.040, and 0.001, respectively) and survival (P = 0.034, 0.001, and 0.006, respectively). The DUSP7-SIHA cells proliferated slower than NC-SIHA cells, based on a clear delay in the doubling time (47.72±1.14 h vs. 23.99±0.47 h, P = 0.0001). Cell cycle analysis indicated that the DUSP7-SIHA cells displayed a concomitant decrease in the percentage of cells in S phase (37.71±0.53% vs. 46.96±0.59%, P < 0.0001) and a significant increase in the percentage of cells in G0/G1 phase (52.50±3.49% vs. 44.04±0.71%, P = 0.0473) suggesting that inhibited proliferation of DUSP7-SIHA cells might be due to the inactivation of DNA synthesis. E-cadherin increased but Vimentin was reduced in DUSP7-SIHA cells, which demonstrated that overexpression of DUSP7 had a potential role in inhibiting EMT of SIHA cells.
Conclusions
The biological function of DUSP7 was possibly achieved through dephosphorylation of the ERK1/2 and inactivation of the RAS pathway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beijing Chaoyang Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)
Presenter: Agnieszka Badora-Rybicka
Session: Poster Display session 2
Resources:
Abstract
4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 2
Resources:
Abstract
5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients
Presenter: Ulku Yalcintas Arslan
Session: Poster Display session 2
Resources:
Abstract
5943 - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results
Presenter: Samir Beslija
Session: Poster Display session 2
Resources:
Abstract
1725 - Final results of scalp cooling for hair preservation: A single- institution prospective study.
Presenter: Dario Loparco
Session: Poster Display session 2
Resources:
Abstract
3713 - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice
Presenter: Lowell Hart
Session: Poster Display session 2
Resources:
Abstract
818 - Management of early breast cancer in women over 90: A 10 year experience
Presenter: Emily Coffey
Session: Poster Display session 2
Resources:
Abstract
1141 - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.
Presenter: Daniel Reinhorn
Session: Poster Display session 2
Resources:
Abstract
2277 - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
Presenter: Zewen Zhang
Session: Poster Display session 2
Resources:
Abstract
2781 - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors : 36-month results
Presenter: Koichi Sakaguchi
Session: Poster Display session 2
Resources:
Abstract